Tartu Linn

• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di … Recruiting
  2023-507518-28-00 5 2022-09-13 Acute myeloid leukemia
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• Study to assess the maintenance of effect of NBI-1065845 as an adjunctive treatment in participants with Major Depressive Disorder (MDD) Recruiting
  2025-520541-72-00 5 2025-10-22 Major Depressive Disorder
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab … Recruiting
  2024-519827-16-00 5 2025-09-30 Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
• Senicapoc in patients with progressive fibrotic interstitial lung disease Recruiting
  2024-511131-97-00 4 2025-08-10 Progressive Fibrotic Interstitial Lung Disease
• A study on the immune response and safety of an investigational chickenpox vaccine when given to healthy children 12 to 15 months of age. Recruiting
  2024-515869-33-00 5 2025-07-08 Varicella
• A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting
  2024-513111-27-00 5 2025-06-26 Psoriatic Arthritis
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• LSTA1 for subjects with newly diagnosed Glioblastoma Multiforme when added to standard of care (temozolomide) versus temozolomide Recruiting
  2023-506813-23-00 4 2023-12-18 Glioblastoma Multiforme
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 5 2023-07-14 Acute Myeloid Leukemia
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 10 2020-07-13 Acute Lymphoblastic Leukaemia
• Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy Recruiting
  2024-517854-91-00 5 2019-08-05 Metastatic or high-risk recurrent prostate cancer managed with androge
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended recruitment
  2024-519743-15-00 5 2025-10-20 Influenza immunisation
• Study of the Safety and lmmunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, T … Ended recruitment
  2024-512271-13-00 5 2025-05-08 Pneumococcal immunisation
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• The Pragmatic EE-PRS Trial assessing Polygenic Risk Driven Statin Therapy for Cardiovascular Disease Prevention Ended recruitment
  2024-513424-42-01 6 2025-03-25 High polygenic risk for coronary artery disease
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis

Showing 25–48 of 127 trials